Can a targeted antibody boost chemotherapy for a rare bile duct cancer?
NCT ID NCT07723534
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding zolbetuximab, an antibody that targets a protein called claudin 18.2, to standard chemotherapy can help control advanced or metastatic biliary tract cancers. The study enrolls adults whose tumors overexpress this protein. Participants receive zolbetuximab with either of two chemotherapy regimens for up to two years, and researchers track how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zolbetuximab combined with chemotherapy (mFOLFOX6 or CAPOX)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced biliary tract cancers that have a specific protein marker.
- What could go wrong
- This is an early-phase trial with only 32 participants, so results may not apply broadly. Chemotherapy side effects and potential immune reactions to zolbetuximab are risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail aims to tame deadly bile duct cancer
- Supercharged immune cells take on bile duct cancer in early trial
- New cocktail of drugs shows promise for bile duct cancer
- New drug cocktail targets cancers missing key gene
- New drug cocktail shows promise for tough bile duct cancer
- Immunotherapy duo takes on rare cancers